View ValuationVimian Group 将来の成長Future 基準チェック /36Vimian Group利益と収益がそれぞれ年間28%と8.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に9.2% 26.1%なると予測されています。主要情報28.0%収益成長率26.15%EPS成長率Medical Equipment 収益成長16.1%収益成長率8.7%将来の株主資本利益率9.17%アナリストカバレッジLow最終更新日18 Feb 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 29Vimian Group AB (publ) to Report Fiscal Year 2026 Results on Feb 11, 2027Vimian Group AB (publ) announced that they will report fiscal year 2026 results on Feb 11, 2027お知らせ • Dec 24Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family.Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family on December 23, 2025. The acquisition is financed with available funds. Following the acquisition, I-Vet will be integrated into Vimian’s Diagnostics segment, and CEO Daniele Franzini will continue to lead I-Vet as part of Vimian. For the period ending December 31, 2024, I-Vet S.R.L. reported total revenue of €5.6 million and has 75 team members. The acquisition is expected to be completed on or around March 2, 2026. The acquisition is expected to have marginal impact on earnings per share in the 2026 financial year.お知らせ • Nov 24+ 1 more updateVimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appointed Alireza Tajbakhsh as Chief Executive Officer, effective 24 November 2025. Alireza Tajbakhsh joined Vimian in 2021 and is currently Head of the Veterinary Services segment and interim Head of the MedTech segment in Vimian. Alireza Tajbakhsh (42) brings extensive international leadership experience from fast-growing entrepreneurial companies in the media and life science sectors. Since joining Vimian in 2021, he has successfully led the Veterinary Services segment and served as a member of the group management team. Since July 2025, he has also held the interim position as Head of Vimian’s MedTech segment, delivering strong early progress and results. Prior to joining Vimian, Alireza held senior management positions at Omnicom Media Group and Modern Times Group (MTG). Alireza holds an M.Sc. in Business and Administration from the Stockholm School of Economics. The board thank Carl-Johan Zetterberg Boudrie for capably serving as interim CEO in addition to his role as CFO over the past months. Carl-Johan Zetterberg will continue as a strong partner to Ali in his position as CFO. Alireza Tajbakhsh will, in addition to the role as Group CEO, continue to hold the interim operational responsibility for Vimian's MedTech segment, while the recruitment for a permanent Head of MedTech is ongoing.お知らせ • Oct 20Vimian Group AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Vimian Group AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026お知らせ • Sep 23Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026.お知らせ • Sep 16+ 2 more updatesVimian Group AB (publ) to Report Q1, 2026 Results on Apr 29, 2026Vimian Group AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Jul 18+ 1 more updateVimian Group AB Announces Executive Management Changes, Effective 17 July 2025Vimian Group AB announced that effective today, Alireza Tajbakhsh will, in addition to his current role as Head of Vimian’s Veterinary Services segment, assume interim operational responsibility for Vimian’s MedTech segment. He succeeds Guy Spörri, who has decided to leave the company at year-end. Furthermore, Bart Bremer, Chief People Officer, is appointed as a member of Vimian’s executive management team.お知らせ • Jun 13Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc.Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc. on June 13, 2025. AllAccem Inc. had revenues of around $9 million for the twelve months ending April 2025, and an EBITDA margin significantly above the Vimian Group average. AllAccem will become part of Vimian’s MedTech segment and Jeffery Whiteford, founder and CEO of AllAccem Inc., will continue to lead the integrated business. The acquisition is expected to have marginal impact on earnings per share in the current financial year. The acquisition of AllAccem Inc. is expected to be completed on or around 13 June and is financed with available funds.お知らせ • Apr 30Vimian Group AB (publ) Elects Pia Marions as Board MemberVimian Group AB (publ) at its Annual General Meeting held on 29 April 2025, Pia Marions was newly elected, as Board members for the time until the end of the next Annual General Meeting.お知らせ • Mar 14Vimian Group AB (publ) to Report Q4, 2025 Results on Feb 12, 2026Vimian Group AB (publ) announced that they will report Q4, 2025 results on Feb 12, 2026お知らせ • Dec 04+ 3 more updatesVimian Group AB (publ) to Report Q2, 2025 Results on Jul 18, 2025Vimian Group AB (publ) announced that they will report Q2, 2025 results on Jul 18, 2025お知らせ • Oct 12Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025.お知らせ • May 23Vimian Group AB (publ) Elects Magnus Welander to Board as Chairman of the BoardVimian Group AB (publ) at its Annual General Meeting held on 22 May 2024 announced that Magnus Welander was newly elected, as Board members for the time until the end of the next Annual General Meeting. Magnus Welander was elected as chairman of the Board.お知らせ • Apr 05Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion.Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,302,624 Price\Range: SEK 25 Transaction Features: Regulation S; Rights Offeringお知らせ • Dec 22Vimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appoints Patrik Eriksson Chief Executive Officer, effective 1 January 2024. Patrik Eriksson joins Vimian from Envista, a global dental company listed on NYSE, where he currently serves on the Executive Team as President of Nobel Biocare. Patrik Eriksson (56) has vast international experience from 25 years as general manager in the global medtech and life science industries. Since 2020, he is President of the dental company Nobel Biocare, part of Envista. Prior to that, he worked seven years at the global life sciences group Danaher (NYSE:DHR) as President of two of its medtech companies, KavoKerr and Ormco. He has led international organizations with more than 6,500 employees and revenues of USD 1.5 billion. He is a Swedish citizen and holds a M.Sc. in Business and Administration from the Stockholm School of Economics. Patrik Eriksson succeeds Fredrik Ullman whose departure at year-end was announced on 29 June 2023.お知らせ • Sep 26Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million.Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million on September 21, 2023. Fidelio Capital completed the acquisition of a 12% stake in Vimian Group AB (publ) on September 21, 2023.お知らせ • Sep 13+ 5 more updatesVimian Group AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vimian Group AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024お知らせ • Jun 30Vimian Group AB (publ) Announces Fredrik Ullman Step Down as CEOVimian Group AB (publ) announced that CEO Fredrik Ullman, following consultation with the Board, steps down as CEO. Fredrik Ullman has been the CEO of Vimian since its inception in 2020 and the CEO of its subsidiary Indical Bioscience since 2018. The recruitment process for a new CEO will be initiated immediately with Fredrik Ullman remaining as CEO in the interim and at the latest until year-end. The recruitment process for a new CEO will be initiated immediately and Fredrik Ullman will remain as CEO in the interim.お知らせ • Jun 03Vimian Group AB (Publ) Elects Robert Belkic as New Board MemberVimian Group AB (publ) at the Annual General Meeting 2 June 2023, announced Robert Belkic was newly elected, as Board members for the time until the end of the next Annual General Meeting.お知らせ • Nov 17+ 2 more updatesVimian Group AB (publ) to Report Q2, 2023 Results on Aug 17, 2023Vimian Group AB (publ) announced that they will report Q2, 2023 results on Aug 17, 2023お知らせ • Oct 25Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023.業績と収益の成長予測OTCPK:VIMG.F - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20285538083117312/31/20275067167100412/31/2026463576089412/31/20254253191106N/A9/30/2025421326075N/A6/30/2025404236680N/A3/31/2025391195164N/A12/31/2024375194458N/A9/30/202435203651N/A6/30/2024345103146N/A3/31/20243358-34-18N/A12/31/202333210-43-29N/A9/30/2023325-5-36-25N/A6/30/2023316-14-53-42N/A3/31/2023301-7515N/A12/31/2022281-71525N/A9/30/202225516-63N/A6/30/202222517314N/A3/31/20221984518N/A12/31/20211737516N/A9/30/202115358919N/A6/30/202113258717N/A3/31/202110460614N/A12/31/20207153-15N/A12/31/201925-102N/A12/31/20188-1N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: VIMG.Fの予測収益成長率 (年間28% ) は 貯蓄率 ( 3.4% ) を上回っています。収益対市場: VIMG.Fの収益 ( 28% ) はUS市場 ( 16.7% ) よりも速いペースで成長すると予測されています。高成長収益: VIMG.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: VIMG.Fの収益 ( 8.7% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: VIMG.Fの収益 ( 8.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: VIMG.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 9.2 %)。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/16 21:08終値2025/12/17 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vimian Group AB (publ) 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関null nullABG Sundal CollierJonathon UnwinBarclaysKristofer Liljeberg-SvenssonCarnegie Investment Bank AB7 その他のアナリストを表示
お知らせ • Apr 29Vimian Group AB (publ) to Report Fiscal Year 2026 Results on Feb 11, 2027Vimian Group AB (publ) announced that they will report fiscal year 2026 results on Feb 11, 2027
お知らせ • Dec 24Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family.Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family on December 23, 2025. The acquisition is financed with available funds. Following the acquisition, I-Vet will be integrated into Vimian’s Diagnostics segment, and CEO Daniele Franzini will continue to lead I-Vet as part of Vimian. For the period ending December 31, 2024, I-Vet S.R.L. reported total revenue of €5.6 million and has 75 team members. The acquisition is expected to be completed on or around March 2, 2026. The acquisition is expected to have marginal impact on earnings per share in the 2026 financial year.
お知らせ • Nov 24+ 1 more updateVimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appointed Alireza Tajbakhsh as Chief Executive Officer, effective 24 November 2025. Alireza Tajbakhsh joined Vimian in 2021 and is currently Head of the Veterinary Services segment and interim Head of the MedTech segment in Vimian. Alireza Tajbakhsh (42) brings extensive international leadership experience from fast-growing entrepreneurial companies in the media and life science sectors. Since joining Vimian in 2021, he has successfully led the Veterinary Services segment and served as a member of the group management team. Since July 2025, he has also held the interim position as Head of Vimian’s MedTech segment, delivering strong early progress and results. Prior to joining Vimian, Alireza held senior management positions at Omnicom Media Group and Modern Times Group (MTG). Alireza holds an M.Sc. in Business and Administration from the Stockholm School of Economics. The board thank Carl-Johan Zetterberg Boudrie for capably serving as interim CEO in addition to his role as CFO over the past months. Carl-Johan Zetterberg will continue as a strong partner to Ali in his position as CFO. Alireza Tajbakhsh will, in addition to the role as Group CEO, continue to hold the interim operational responsibility for Vimian's MedTech segment, while the recruitment for a permanent Head of MedTech is ongoing.
お知らせ • Oct 20Vimian Group AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Vimian Group AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026
お知らせ • Sep 23Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026.
お知らせ • Sep 16+ 2 more updatesVimian Group AB (publ) to Report Q1, 2026 Results on Apr 29, 2026Vimian Group AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Jul 18+ 1 more updateVimian Group AB Announces Executive Management Changes, Effective 17 July 2025Vimian Group AB announced that effective today, Alireza Tajbakhsh will, in addition to his current role as Head of Vimian’s Veterinary Services segment, assume interim operational responsibility for Vimian’s MedTech segment. He succeeds Guy Spörri, who has decided to leave the company at year-end. Furthermore, Bart Bremer, Chief People Officer, is appointed as a member of Vimian’s executive management team.
お知らせ • Jun 13Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc.Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc. on June 13, 2025. AllAccem Inc. had revenues of around $9 million for the twelve months ending April 2025, and an EBITDA margin significantly above the Vimian Group average. AllAccem will become part of Vimian’s MedTech segment and Jeffery Whiteford, founder and CEO of AllAccem Inc., will continue to lead the integrated business. The acquisition is expected to have marginal impact on earnings per share in the current financial year. The acquisition of AllAccem Inc. is expected to be completed on or around 13 June and is financed with available funds.
お知らせ • Apr 30Vimian Group AB (publ) Elects Pia Marions as Board MemberVimian Group AB (publ) at its Annual General Meeting held on 29 April 2025, Pia Marions was newly elected, as Board members for the time until the end of the next Annual General Meeting.
お知らせ • Mar 14Vimian Group AB (publ) to Report Q4, 2025 Results on Feb 12, 2026Vimian Group AB (publ) announced that they will report Q4, 2025 results on Feb 12, 2026
お知らせ • Dec 04+ 3 more updatesVimian Group AB (publ) to Report Q2, 2025 Results on Jul 18, 2025Vimian Group AB (publ) announced that they will report Q2, 2025 results on Jul 18, 2025
お知らせ • Oct 12Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025.
お知らせ • May 23Vimian Group AB (publ) Elects Magnus Welander to Board as Chairman of the BoardVimian Group AB (publ) at its Annual General Meeting held on 22 May 2024 announced that Magnus Welander was newly elected, as Board members for the time until the end of the next Annual General Meeting. Magnus Welander was elected as chairman of the Board.
お知らせ • Apr 05Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion.Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,302,624 Price\Range: SEK 25 Transaction Features: Regulation S; Rights Offering
お知らせ • Dec 22Vimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appoints Patrik Eriksson Chief Executive Officer, effective 1 January 2024. Patrik Eriksson joins Vimian from Envista, a global dental company listed on NYSE, where he currently serves on the Executive Team as President of Nobel Biocare. Patrik Eriksson (56) has vast international experience from 25 years as general manager in the global medtech and life science industries. Since 2020, he is President of the dental company Nobel Biocare, part of Envista. Prior to that, he worked seven years at the global life sciences group Danaher (NYSE:DHR) as President of two of its medtech companies, KavoKerr and Ormco. He has led international organizations with more than 6,500 employees and revenues of USD 1.5 billion. He is a Swedish citizen and holds a M.Sc. in Business and Administration from the Stockholm School of Economics. Patrik Eriksson succeeds Fredrik Ullman whose departure at year-end was announced on 29 June 2023.
お知らせ • Sep 26Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million.Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million on September 21, 2023. Fidelio Capital completed the acquisition of a 12% stake in Vimian Group AB (publ) on September 21, 2023.
お知らせ • Sep 13+ 5 more updatesVimian Group AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vimian Group AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024
お知らせ • Jun 30Vimian Group AB (publ) Announces Fredrik Ullman Step Down as CEOVimian Group AB (publ) announced that CEO Fredrik Ullman, following consultation with the Board, steps down as CEO. Fredrik Ullman has been the CEO of Vimian since its inception in 2020 and the CEO of its subsidiary Indical Bioscience since 2018. The recruitment process for a new CEO will be initiated immediately with Fredrik Ullman remaining as CEO in the interim and at the latest until year-end. The recruitment process for a new CEO will be initiated immediately and Fredrik Ullman will remain as CEO in the interim.
お知らせ • Jun 03Vimian Group AB (Publ) Elects Robert Belkic as New Board MemberVimian Group AB (publ) at the Annual General Meeting 2 June 2023, announced Robert Belkic was newly elected, as Board members for the time until the end of the next Annual General Meeting.
お知らせ • Nov 17+ 2 more updatesVimian Group AB (publ) to Report Q2, 2023 Results on Aug 17, 2023Vimian Group AB (publ) announced that they will report Q2, 2023 results on Aug 17, 2023
お知らせ • Oct 25Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023.